Personalised treatment for the most common form of adult leukaemia helps patients survive for longer and stay in remission, a phase III trial has found.
Scripps Research scientists have developed a new strategy for identifying small molecules that can change the function of proteins, offering a promising path for discovering targeted drugs.
The researchers developed a tool, a computational algorithm that calculates a clonal hematopoiesis risk score (CHRS) to predict future blood cancer risk.